Comment
Author: Admin | 2025-04-28
End up with higher-than-average systemic concentrations of Lexapro. If a poor CYP2C19 metabolizer initiates treatment with a high dose of Lexapro, its effect may be pronounced earlier in treatment largely due to the fact that poor CYP2C19 metabolism yields more substantial exposure to the medication. (This is why it’s recommended to start at 50% of a normal Lexapro dose if your genetics indicate poor CYP2C19 metabolism).On the other hand, someone expressing genes that yield rapid or ultrarapid CYP2C19 metabolism may be less likely to notice the medication working early in treatment. A rapid CYP2C19 metabolizer may need 8 weeks of treatment and dosage increases thereafter to derive a therapeutic benefit, largely due to the fact that rapid CYP2C19 metabolism reduces exposure to the medication. In fact, persons classified as CYP2C19 ultrarapid metabolizers may not even respond to Lexapro – or notice it working because systemic exposure is so minimal.In addition to genes implicated in Lexapro pharmacokinetics, there may be genes that predict how effectively interacts with various neurochemical targets. For example, variants in the 5-HTTPLR gene may influence the amount of benefit someone derives from Lexapro, as well as how long it takes for the medication to start working.Source: https://www.pharmgkb.org/guideline/PA166127638Source: https://www.ncbi.nlm.nih.gov/pubmed/17146470/Substance use prior to LexaproIf you used substances prior to taking Lexapro, particularly substances that modulate neurotransmitters in the central nervous system, you may respond faster or slower than average to Lexapro. For example, if you recently used an SSRI for several weeks and then suddenly switched from the old
Add Comment